Bolsas y Mercados Españoles
Company
search
ORYZON GENOMICS, S.A.
AddressCARRERA DE SAN JERÓNIMO 15, 28014 MADRID 
Listed Capital2,737,172.00 Euros

 


ORYZON GENOMICS
ISINES0167733015 TickerORY Nominal0.05 MarketContinuous Market Admitted Capital2,737,172.00 Euros 

Last prices
DateHourCloseRef.% Dif.LastHighLowAvg.VolumeTurnover
09/12/202214:07:41- 2.0600-0.972.04002.06002.01002.0276137,293278,379.17
08/12/2022Close2.06002.0800-0.962.06002.11502.02002.0492146,651300,515.34
X
09/12/2022 14:08:24
BidAsk
OrdersVolumePricePriceVolumeOrders
42,1152.02502.04001,1782
Data Delayed 15 minutes.

Last pay
TypeEx-datePayment DateConcept
 

Last split
DateEquivalence
 

Last reverse split
DateEquivalence
 

Last capital increase
PeriodProportionType
30/11/202214 x 1,000Premium


 2022
until 8/12
2021202020192018
Capitalisation *
(thousands of euros)
112,771143,270185,720127,29684,702
Shares
(x 1,000)
54,74353,06353,06345,79039,123
Period Close Price
(euros)
2.06002.70003.50002.78002.1650
Period Last Price
(euros)
2.06002.70003.50002.78002.1650
Period High Price
(euros)
3.35004.39503.89504.46505.1800
Period Low Price
(euros)
1.98202.62501.47602.11502.0450
Volume
(thousands of shares)
28,96561,45491,82578,11395,258
Turnover
(thousands of euros)
74,912226,749285,561260,089336,854

Profile

ORYZON is a public clinical stage biopharmaceutical company and the European leader in the development of epigenetics-based therapeutics, with a strong focus on personalized medicine approaches to CNS disorders and oncology.

Our business model is to develop our proprietary drug candidates through clinical Phase II, at which point we decide on a case-by-case basis to either keep the development in-house or to partner or out-license the compound for late stage development and commercialization.

ORYZON has been listed on the Spanish Stock Exchange since December 2015 (ORY, ISIN Code: ES0167733015). Since then, the company has attracted specialized investors from US, Israel and Europe in several PIPEs led by different US investment banks.
The company has a broad and growing portfolio, with two compounds in Phase II clinical trials: iadademstat (aka ORY-1001), a highly potent and selective LSD1 inhibitor that has been granted orphan-drug status by EMA, for oncology, and vafidemstat (aka ORY-2001), a CNS optimized LSD1 inhibitor for the treatment of neurological diseases. Our pipeline also includes ORY-3001, a selective LSD1 inhibitor in preclinical development for the treatment of non-oncological diseases, and additional programs at advanced stages of preclinical development, such as HDAC-6 inhibitors.

The entire portfolio has been created internally from a concerted effort of our functional genomics, medicinal chemistry, preclinical and clinical development teams. The company has a very solid IP position and is the originator and owner of all our IP portfolio.

The company has a seasoned international executive management with vast experience in the industry.ORYZON has offices in Spain and the United States.

Source: Issuing company.
09/12/2022 00:09:10

To obtain detailed information or information in other formats, please contact BME Market Data at marketdata@grupobme.es or visit the website www.bmemarketdata.es.

The information provided by the different websites of Grupo BME is for internal use only. For any commercial use and/or other usage that involves the redistribution of the information to third parties for a fee, it is required a prior and express permission from BME Market Data. Please contact us at marketdata@grupobme.es.

Follow us in:
Copyright © BME 2022